[Form 4] LeMaitre Vascular, Inc. Insider Trading Activity
Bridget A. Ross, a director of LeMaitre Vascular (LMAT), reported exercising 2,500 vested stock options on 08/08/2025 with an exercise price of $37.29, and concurrently selling 2,500 common shares at $94.00 per share. The option exercised was fully vested and had an expiration date of 12/02/2025. The sequence increased her direct holdings to 5,416 shares then, after the sale, left her with 2,916 shares of common stock beneficially owned.
Bridget A. Ross, direttrice di LeMaitre Vascular (LMAT), ha comunicato di aver esercitato 2,500 opzioni su azioni gi脿 maturate il 08/08/2025 con un prezzo di esercizio di $37.29, e contemporaneamente di aver venduto 2,500 azioni ordinarie a $94.00 ciascuna. L'opzione esercitata era completamente maturata ed aveva scadenza il 12/02/2025. L'operazione ha portato le sue partecipazioni dirette a 5,416 azioni e, dopo la vendita, le ha lasciato 2,916 azioni ordinarie di cui 猫 beneficiaria.
Bridget A. Ross, directora de LeMaitre Vascular (LMAT), inform贸 que ejerci贸 2,500 opciones sobre acciones ya adquiridas el 08/08/2025 con un precio de ejercicio de $37.29, y simult谩neamente vendi贸 2,500 acciones comunes a $94.00 por acci贸n. La opci贸n ejercida estaba totalmente adquirida y venc铆a el 12/02/2025. La operaci贸n aument贸 sus tenencias directas a 5,416 acciones y, tras la venta, le dej贸 2,916 acciones ordinarias de las que es beneficiaria.
LeMaitre Vascular(LMAT) 鞚挫偓鞚� Bridget A. Ross電� 08/08/2025鞐� 頄夓偓 臧�瓴╈澊 $37.29鞚� 2,500欤检潣 鞕勳爠 旆摑(vested) 欤检嫕毵れ垬靹犿儩甓岇潉 頄夓偓頃橁碃, 霃欖嫓鞐� 氤错喌欤� 2,500欤茧ゼ 欤茧嫻 $94.00鞐� 毵る弰頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 頄夓偓霅� 鞓奠厴鞚� 鞕勳爠頌� 旆摑霅� 靸來儨鞓�鞙茧┌ 毵岅赴鞚检潃 12/02/2025鞓�鞀惦媹雼�. 鞚� 瓯半灅搿� 攴鸽厐鞚� 歆侅爲 氤挫湢 欤检嫕鞚� 5,416欤缄皜 霅橃棃瓿�, 毵る弰 頉勳棎電� 2,916欤检潣 氤错喌欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�.
Bridget A. Ross, administratrice de LeMaitre Vascular (LMAT), a d茅clar茅 avoir exerc茅 2,500 options d'achat d'actions acquises le 08/08/2025 au prix d'exercice de $37.29, et simultan茅ment vendu 2,500 actions ordinaires 脿 $94.00 l'une. L'option exerc茅e 茅tait enti猫rement acquise et arrivait 脿 茅ch茅ance le 12/02/2025. L'op茅ration a port茅 ses participations directes 脿 5,416 actions et, apr猫s la vente, elle d茅tenait 2,916 actions ordinaires dont elle est b茅n茅ficiaire.
Bridget A. Ross, Direktorin von LeMaitre Vascular (LMAT), meldete, dass sie am 08/08/2025 2,500 unverfallbare Aktienoptionen zum Aus眉bungspreis von $37.29 ausge眉bt und gleichzeitig 2,500 Stammaktien zum Preis von $94.00 je Aktie verkauft hat. Die ausge眉bte Option war vollst盲ndig unverfallbar und hatte eine Laufzeit bis zum 12/02/2025. Die Transaktion erh枚hte ihren direkten Bestand auf 5,416 Aktien und lie脽 sie nach dem Verkauf mit 2,916 beg眉nstigt gehaltenen Stammaktien zur眉ck.
- None.
- None.
Insights
TL;DR: Director exercised vested options and sold the same number of shares; net direct ownership is 2,916 shares.
The filing documents a routine option exercise (2,500 shares at a $37.29 strike) followed immediately by a sale of those 2,500 shares at $94.00. This left the reporting director with 2,916 directly owned shares. The option was fully vested with a 12/02/2025 expiration, so there is no remaining derivative position from that grant. From a market-impact perspective this is a single-person insider liquidity event and does not, by itself, indicate a change in company fundamentals.
TL;DR: Disclosure shows a vested-option exercise and disposition by a director; the report is complete and notes vesting and expiration.
The Form 4 discloses both the acquisition from option exercise and the contemporaneous disposition of the same 2,500 shares, with clear reporting of prices and post-transaction share counts. The explanatory footnotes explicitly state the shares were acquired upon exercise and that the option was fully vested and exercisable. This meets standard Section 16 transparency expectations; the filing contains no additional governance actions or changes in role.
Bridget A. Ross, direttrice di LeMaitre Vascular (LMAT), ha comunicato di aver esercitato 2,500 opzioni su azioni gi脿 maturate il 08/08/2025 con un prezzo di esercizio di $37.29, e contemporaneamente di aver venduto 2,500 azioni ordinarie a $94.00 ciascuna. L'opzione esercitata era completamente maturata ed aveva scadenza il 12/02/2025. L'operazione ha portato le sue partecipazioni dirette a 5,416 azioni e, dopo la vendita, le ha lasciato 2,916 azioni ordinarie di cui 猫 beneficiaria.
Bridget A. Ross, directora de LeMaitre Vascular (LMAT), inform贸 que ejerci贸 2,500 opciones sobre acciones ya adquiridas el 08/08/2025 con un precio de ejercicio de $37.29, y simult谩neamente vendi贸 2,500 acciones comunes a $94.00 por acci贸n. La opci贸n ejercida estaba totalmente adquirida y venc铆a el 12/02/2025. La operaci贸n aument贸 sus tenencias directas a 5,416 acciones y, tras la venta, le dej贸 2,916 acciones ordinarias de las que es beneficiaria.
LeMaitre Vascular(LMAT) 鞚挫偓鞚� Bridget A. Ross電� 08/08/2025鞐� 頄夓偓 臧�瓴╈澊 $37.29鞚� 2,500欤检潣 鞕勳爠 旆摑(vested) 欤检嫕毵れ垬靹犿儩甓岇潉 頄夓偓頃橁碃, 霃欖嫓鞐� 氤错喌欤� 2,500欤茧ゼ 欤茧嫻 $94.00鞐� 毵る弰頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 頄夓偓霅� 鞓奠厴鞚� 鞕勳爠頌� 旆摑霅� 靸來儨鞓�鞙茧┌ 毵岅赴鞚检潃 12/02/2025鞓�鞀惦媹雼�. 鞚� 瓯半灅搿� 攴鸽厐鞚� 歆侅爲 氤挫湢 欤检嫕鞚� 5,416欤缄皜 霅橃棃瓿�, 毵る弰 頉勳棎電� 2,916欤检潣 氤错喌欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�.
Bridget A. Ross, administratrice de LeMaitre Vascular (LMAT), a d茅clar茅 avoir exerc茅 2,500 options d'achat d'actions acquises le 08/08/2025 au prix d'exercice de $37.29, et simultan茅ment vendu 2,500 actions ordinaires 脿 $94.00 l'une. L'option exerc茅e 茅tait enti猫rement acquise et arrivait 脿 茅ch茅ance le 12/02/2025. L'op茅ration a port茅 ses participations directes 脿 5,416 actions et, apr猫s la vente, elle d茅tenait 2,916 actions ordinaires dont elle est b茅n茅ficiaire.
Bridget A. Ross, Direktorin von LeMaitre Vascular (LMAT), meldete, dass sie am 08/08/2025 2,500 unverfallbare Aktienoptionen zum Aus眉bungspreis von $37.29 ausge眉bt und gleichzeitig 2,500 Stammaktien zum Preis von $94.00 je Aktie verkauft hat. Die ausge眉bte Option war vollst盲ndig unverfallbar und hatte eine Laufzeit bis zum 12/02/2025. Die Transaktion erh枚hte ihren direkten Bestand auf 5,416 Aktien und lie脽 sie nach dem Verkauf mit 2,916 beg眉nstigt gehaltenen Stammaktien zur眉ck.
